TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3318574

Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol combined with atropine sulfate
Number of subjects: 35

Group type: COMPARATOR
Intervention: Inhaled atropine sulfate
Number of subjects: 35
Study: 29861218

Group type: EXPERIMENTAL
Intervention: Kinesiology tape application
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Kinesiology tape with EMLA
Number of subjects: 20

Group type: COMPARATOR
Intervention: EMLA
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tape application
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control without kinesiology tape or EMLA
Number of subjects: 20
Study: 28215835

Group type: EXPERIMENTAL
Intervention: Early endoscopic treatment (ET) with prophylaxis until resolution
Number of subjects: 77

Group type: COMPARATOR
Intervention: Continuous antibiotic prophylaxis (CAP)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Both ET and CAP
Number of subjects: 77
Study: 26200017

Group type: EXPERIMENTAL
Intervention: FAST (maximal cadence before test)
Number of subjects: 28
Study: 23980148

Group type: EXPERIMENTAL
Intervention: Speech-like auditory stimuli exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prenatal speech exposure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalization of learning effect
Number of subjects: 0
Study: 21429706

Group type: EXPERIMENTAL
Intervention: Home-based constraint-induced therapy (CIT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Dose-matched home-based control intervention
Number of subjects: 21
Study: 18328855

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 22926
Study: 16340722

Group type: EXPERIMENTAL
Intervention: Region-of-interest (ROI) template for Z-score images of 3-D stereotactic surface projections (3-D SSP)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Visual inspection of Z-score images
Number of subjects: 25
Study: 14552104

Group type: EXPERIMENTAL
Intervention: Epidural methadone (epPCA group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous methadone (ivPCA group)
Number of subjects: 30
Study: 12706639

Group type: EXPERIMENTAL
Intervention: bemiparin (3500 IU, anti-Xa)
Number of subjects: 12

Group type: COMPARATOR
Intervention: tinzaparin (4500 IU, anti-Xa)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: both formulations
Number of subjects: 12
Study: 10494485

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal ring (1 mg NET‐Ac and 20 micrograms EE daily)
Number of subjects: 60
Study: 8945028

Group type: EXPERIMENTAL
Intervention: Autosensing feature activated
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Autosensing adjusted sensitivity
Number of subjects: 55

Group type: COMPARATOR
Intervention: Autosensing compared to recommended 2:1 safety margin
Number of subjects: 55
Study: 1994405

Group type: EXPERIMENTAL
Intervention: MR angiography
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Color duplex ultrasound (US)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Conventional angiography
Number of subjects: 12
Study: 6400709

Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg before the evening meal
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Acarbose 200 mg
Number of subjects: 14
Study: 3915888

Group type: EXPERIMENTAL
Intervention: Tenoxicam 40 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Piroxicam 40 mg/day
Number of subjects: 30
Study: 29735967

Group type: EXPERIMENTAL
Intervention: Modified Yanghe Decoction
Number of subjects: 80

Group type: COMPARATOR
Intervention: Celecoxib-sulfasalazine
Number of subjects: 80
Study: 28735464

Group type: EXPERIMENTAL
Intervention: Low-dose protocol
Number of subjects: 50

Group type: COMPARATOR
Intervention: High-dose protocol
Number of subjects: 50
Study: 26495694

Group type: EXPERIMENTAL
Intervention: BCP/PLGA
Number of subjects: 24

Group type: COMPARATOR
Intervention: P-TCP
Number of subjects: 24

Group type: COMPARATOR
Intervention: DPBB
Number of subjects: 24
Study: 24065010

Group type: EXPERIMENTAL
Intervention: Low-glucose suspension group (automated insulin suspension)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Pump-only therapy (standard insulin pump)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 95
Study: 22117998

Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg, daily, orally for 8 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 18271772

Group type: EXPERIMENTAL
Intervention: Fuji VII glass ionomer cement (GIC) applied to the cervical third of posterior teeth
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control side (no GIC applied)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Retention of GIC
Number of subjects: 100
Study: 16510486

Group type: EXPERIMENTAL
Intervention: Ecstasy use during the 9-day assessment period
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Ecstasy use
Number of subjects: 38
Study: 12633548

Group type: EXPERIMENTAL
Intervention: Active treatment with perindopril (4 mg daily) and indapamide (at physician's discretion)
Number of subjects: 6105

Group type: EXPERIMENTAL
Intervention: Active treatment with perindopril and indapamide
Number of subjects: 6105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6105
Study: 11808057

Group type: EXPERIMENTAL
Intervention: 10% chlorhexidine varnish treatment
Number of subjects: 236

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 236

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 236
Study: 9209249

Group type: EXPERIMENTAL
Intervention: 5 mg minoxidil
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2.5 mg glyburide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5 mg minoxidil with 2.5 mg glyburide
Number of subjects: 9

Group type: COMPARATOR
Intervention: 5 mg glyburide
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 5 mg glyburide with 5 mg minoxidil
Number of subjects: 9
Study: 8417730

Group type: EXPERIMENTAL
Intervention: Pain‐Related Self Statements Scale (PRSS) - Catastrophizing
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Pain‐Related Self Statements Scale (PRSS) - Coping
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Pain‐Related Control Scale (PRCS) - Helplessness
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: Pain‐Related Control Scale (PRCS) - Resourcefulness
Number of subjects: 415
Study: 3744299

Group type: EXPERIMENTAL
Intervention: triazolam
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 31096794

Group type: EXPERIMENTAL
Intervention: Microneedling with topical bleomycin at 2 weeks interval
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Intralesional bleomycin at 3 weeks interval
Number of subjects: 54

Group type: COMPARATOR
Intervention: Intralesional saline (control)
Number of subjects: 54
Study: 30101332

Group type: EXPERIMENTAL
Intervention: LCHP+ω‐3 diet
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: LCHP diet
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: ω‐3 diet
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control (CON) diet
Number of subjects: 122
Study: 27155210

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 194

Group type: COMPARATOR
Intervention: Control (no antibiotic treatment)
Number of subjects: 194
Study: 24008587

Group type: EXPERIMENTAL
Intervention: T. arjuna bark extract
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vehicle control cream
Number of subjects: 60
Study: 21800222

Group type: EXPERIMENTAL
Intervention: Nasal mask during CPAP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oronasal mask 1 during CPAP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oronasal mask 2 during CPAP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nasal mask during auto-PAP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oronasal masks during auto-PAP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nasal mask and oronasal masks during CPAP and auto-PAP
Number of subjects: 12
Study: 19916063

Group type: EXPERIMENTAL
Intervention: Methamphetamine (20 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Methamphetamine (40 mg)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: MDMA (100 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 18462502

Group type: EXPERIMENTAL
Intervention: Topiramate (200 mg/day)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Nicotine Substitution Therapy (NST)
Number of subjects: 180
Study: 16626425

Group type: EXPERIMENTAL
Intervention: Oral Cox-2 inhibitor prophylaxis of cystoid macular oedema
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Routine cataract surgery
Number of subjects: 62
Study: 12880879

Group type: EXPERIMENTAL
Intervention: Noticing other teens smoking
Number of subjects: 6274

Group type: EXPERIMENTAL
Intervention: Perception that adults care about and disapprove of teen smoking
Number of subjects: 6274

Group type: EXPERIMENTAL
Intervention: Perceived prevalence of smoking
Number of subjects: 6274
Study: 11093486

Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 9120451

Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Gabapentin 1800 mg/day
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Gabapentin 2400 mg/day
Number of subjects: 27

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Gabapentin (all doses)
Number of subjects: 27
Study: 1490748

Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 100
Study: 3894129

Group type: EXPERIMENTAL
Intervention: Conventional insulin treatment or CSII (Continuous Subcutaneous Insulin Infusion)
Number of subjects: 70
Study: 30203671

Group type: COMPARATOR
Intervention: Postoperative topical steroids alone (Group A)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both steroidal and nonsteroidal anti‐inflammatory eye drops (Group B)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 100
Study: 28609362

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 562

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Everolimus with concomitant octreotide treatment
Number of subjects: 562
Study: 25265123

Group type: EXPERIMENTAL
Intervention: FDBA/β‐TCP/platelet‐rich plasma (PRP)/collagen plug
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: FDBA/β‐TCP/recombinant human platelet‐derived growth factor BB (rhPDGF‐BB)/collagen plug
Number of subjects: 41

Group type: COMPARATOR
Intervention: FDBA/β‐TCP/collagen plug
Number of subjects: 41
Study: 23758998

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for type 2 diabetes prevention
Number of subjects: 692

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for dietary and exercise objectives
Number of subjects: 692

Group type: COMPARATOR
Intervention: Usual care for dietary and exercise objectives
Number of subjects: 692

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention for weight loss
Number of subjects: 692

Group type: COMPARATOR
Intervention: Usual care for weight loss
Number of subjects: 692
Study: 21385974

Group type: EXPERIMENTAL
Intervention: Tetanus stimulation at the P6 acupuncture point
Number of subjects: 264

Group type: COMPARATOR
Intervention: ST stimulation over the ulnar nerve (control)
Number of subjects: 264
Study: 18070144

Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (300 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (250 ml of 0.9% sodium chloride)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (250 ml of 0.9% sodium chloride)
Number of subjects: 42
Study: 16480969

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day) in Group A
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional therapy alone in Group B
Number of subjects: 78

Group type: COMPARATOR
Intervention: Atorvastatin vs Conventional therapy alone
Number of subjects: 78
Study: 12527456

Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 86

Group type: COMPARATOR
Intervention: Prostaglandin E2
Number of subjects: 86
Study: 10729395

Group type: COMPARATOR
Intervention: R192 allele in CAD patients
Number of subjects: 431

Group type: COMPARATOR
Intervention: R192 allele in ischemic stroke patients
Number of subjects: 431
Study: 8924191

Group type: EXPERIMENTAL
Intervention: Phentermine (30 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fenfluramine (40 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phentermine (30 mg) with Fenfluramine (40 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: d-Amphetamine (10 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: d-Amphetamine (20 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fenfluramine (80 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Phentermine (30 mg) with Fenfluramine (80 mg)
Number of subjects: 12
Study: 1546398

Group type: EXPERIMENTAL
Intervention: Screening with Hemoccult‐II
Number of subjects: 61938

Group type: COMPARATOR
Intervention: Control group (not screened)
Number of subjects: 61938
Study: 3840743

Group type: EXPERIMENTAL
Intervention: Formulation N (higher plasma fenofibrate level)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Formulation R (lower plasma fenofibrate level)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 11
Study: 29955889

Group type: EXPERIMENTAL
Intervention: Web-based training (Technology)
Number of subjects: 375

Group type: COMPARATOR
Intervention: In-person training (Traditional)
Number of subjects: 375

Group type: EXPERIMENTAL
Intervention: Both training methods
Number of subjects: 375
Study: 29906264

Group type: EXPERIMENTAL
Intervention: SYNTAX II score
Number of subjects: 831

Group type: EXPERIMENTAL
Intervention: Mortality
Number of subjects: 831
Study: 26908701

Group type: EXPERIMENTAL
Intervention: Videolaryngoscope (VL)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Classic laryngoscope (CL)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Videolaryngoscope (VL) to Classic laryngoscope (CL)
Number of subjects: 34
Study: 24377403

Group type: EXPERIMENTAL
Intervention: Psychological therapies (Cognitive Behavioral Therapy and Psychoanalytic Therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative study (IMPACT-My Experience)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized Controlled Trial (RCT)
Number of subjects: 0
Study: 22094261

Group type: EXPERIMENTAL
Intervention: Preemptive morphine analgesia (maximum of 14 days)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 20677963

Group type: EXPERIMENTAL
Intervention: Orthodontic oral appliance (orthodontic OA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Orthodontic oral appliance (OA)
Number of subjects: 30
Study: 17242760

Group type: EXPERIMENTAL
Intervention: Fingerprint recognition technology for participant identification
Number of subjects: 0
Study: 15100699

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) 325 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG)
Number of subjects: 12
Study: 12387693

Group type: EXPERIMENTAL
Intervention: Antibiotics (specific type not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10234420

Group type: EXPERIMENTAL
Intervention: Professional touch (participants touched on the wrist to have their pulse taken)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Social touch (unexplained touch to the same area of the arm)
Number of subjects: 125

Group type: COMPARATOR
Intervention: No-touch control (participants told their pulse was being taken automatically without being touched)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Social touch with female experimenters
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Social touch with women being touched by men
Number of subjects: 125
Study: 9203950

Group type: EXPERIMENTAL
Intervention: Laser induced shock wave lithotripsy (LISL)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined LISL and additional fragmentation techniques
Number of subjects: 34
Study: 2008942

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% (175 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bupivacaine 0.5% (175 mg)
Number of subjects: 48
Study: 7261830

Group type: EXPERIMENTAL
Intervention: Elevation of the head of the bed
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bethanechol 25 mg 4 times a day
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Bethanechol combined with head of bed elevation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Antacid foam tablets
Number of subjects: 55
Study: 30528313

Group type: EXPERIMENTAL
Intervention: Cardio-respiratory fitness (CRF) assessed with peak oxygen uptake during maximum exercise
Number of subjects: 80
Study: 28959438

Group type: EXPERIMENTAL
Intervention: Community health worker-led education intervention
Number of subjects: 1934

Group type: COMPARATOR
Intervention: Comparison clusters (control)
Number of subjects: 1934
Study: 24089377

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation (140 ml/day, containing 8 mmol of NO3(‐))
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Beetroot juice (BR) supplementation
Number of subjects: 9
Study: 21868736

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 108

Group type: COMPARATOR
Intervention: Problem-solving therapy
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study: 19485290

Group type: EXPERIMENTAL
Intervention: Titanium:sapphire laser trabeculoplasty (TLT)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Argon laser trabeculoplasty (ALT)
Number of subjects: 37
Study: 17915638

Group type: EXPERIMENTAL
Intervention: Helicidum tablet preparation 1 (75 mg, 3 tablets)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Helicidum tablet preparation 2 (75 mg, 3 tablets)
Number of subjects: 20
Study: 15819302

Group type: EXPERIMENTAL
Intervention: IVUS-guided bare metal stent implantation (BMS)
Number of subjects: 103
Study: 11570966

Group type: EXPERIMENTAL
Intervention: FSH-primed group (150 iu recombinant FSH day(-1) for 3 days)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Non-primed group (no stimulation)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: FSH-primed group
Number of subjects: 28
Study: 9436937

Group type: EXPERIMENTAL
Intervention: Z-Dex (oral idarubicin and dexamethasone)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DHAP (cis-platin, Ara-C and dexamethasone)
Number of subjects: 30

Group type: COMPARATOR
Intervention: LD cyclophosphamide
Number of subjects: 30

Group type: COMPARATOR
Intervention: HD cyclophosphamide
Number of subjects: 30

Group type: COMPARATOR
Intervention: cis-platin/VP16
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DHAP
Number of subjects: 30
Study: 8513039

Group type: EXPERIMENTAL
Intervention: Physostigmine
Number of subjects: 2

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 2
Study: 3106450

Group type: EXPERIMENTAL
Intervention: Cromolyn 20 mg
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Cromolyn 40 mg
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 5
Study: 30075546

Group type: COMPARATOR
Intervention: anti-plasminogen binding peptide (a-PBP)
Number of subjects: 29

Group type: COMPARATOR
Intervention: immunoglobulin G4 (IgG4)
Number of subjects: 29

Group type: COMPARATOR
Intervention: IgG4
Number of subjects: 29

Group type: COMPARATOR
Intervention: c-ANCA
Number of subjects: 29
Study: 27581578

Group type: COMPARATOR
Intervention: Food secure households
Number of subjects: 14600

Group type: EXPERIMENTAL
Intervention: Mild HFI
Number of subjects: 14600

Group type: EXPERIMENTAL
Intervention: Moderate HFI
Number of subjects: 14600

Group type: EXPERIMENTAL
Intervention: Severe HFI
Number of subjects: 14600
Study: 25204507

Group type: EXPERIMENTAL
Intervention: 0.25 μg/kg of dexmedetomidine (low-dose group)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 0.5 μg/kg of dexmedetomidine (subclinical dose group)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 1.0 μg/kg of dexmedetomidine (clinical dose group)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Normal saline (saline group)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: All dexmedetomidine doses
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 138
Study: 22923662

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate 500/125 mg three times a day for 8 days
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo three times a day for 8 days
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 310
Study: 19957178

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Primary stenting
Number of subjects: 35
Study: 18335329

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50 mg on days 3-5
Number of subjects: 22

Group type: COMPARATOR
Intervention: Letrozole 2.5 mg
Number of subjects: 22
Study: 16466009

Group type: EXPERIMENTAL
Intervention: Patients with chronic pancreatitis (CP)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Patients with chronic pancreatitis (CP) at Cambridge IV stage
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 39
Study: 11979494

Group type: EXPERIMENTAL
Intervention: Experimental condition with heuristics (distance-decay and circle hypothesis)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control condition (no heuristics)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Predictions generated by Dragnet (geographic profiling system)
Number of subjects: 21
Study: 10876541

Group type: EXPERIMENTAL
Intervention: Acute Care Nurse Practitioner (ACNP) role
Number of subjects: 0
Study: 7782813

Group type: EXPERIMENTAL
Intervention: Questionnaire administered to patients after decision about participation
Number of subjects: 247